{"id":249985,"date":"2025-06-17T00:00:00","date_gmt":"2025-06-17T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/products\/research-reports\/report\/epidon0058-biopharma-bladder-cancer-epidemiology-mature-markets\/"},"modified":"2026-03-31T10:25:57","modified_gmt":"2026-03-31T10:25:57","slug":"epidon0058-biopharma-bladder-cancer-epidemiology-mature-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidon0058-biopharma-bladder-cancer-epidemiology-mature-markets\/","title":{"rendered":"Bladder Cancer &#8211; Epidemiology &#8211; Mature Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of bladder cancer for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe, and Japan and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in the developed world.<\/p>\n<p>Clarivate Epidemiology\u2019s bladder cancer forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with bladder cancer per year?<\/li>\n<li>How will improvements in survival change the number of people living with a diagnosis of urothelial bladder cancer?<\/li>\n<li>How will the declining risk of recurrence change the number of first-line drug-treatment opportunities for urothelial bladder cancer per year?<\/li>\n<li>Of all people diagnosed with urothelial bladder cancer, how many in each country in the developed world are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of urothelial bladder cancer over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr data-abbreviation-entity=\"10739\" title=\"Microsoft\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graph depicting the patient flow between or within different disease states for the countries considered in this report. These patient-flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.<\/p>\n<p>Clarivate Epidemiology provides at least 10 years of forecast data for the following urothelial bladder cancer patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Diagnosed incident cases of bladder cancer.<\/li>\n<li>Diagnosed incident cases of urothelial bladder cancer.<\/li>\n<li>Diagnosed incident cases of urothelial bladder cancer by stage at diagnosis.<\/li>\n<li>Diagnosed incident cases of urothelial bladder cancer by muscle-invasiveness at diagnosis.<\/li>\n<li>Diagnosed locally recurrent incident cases\u00a0of urothelial bladder cancer.<\/li>\n<li>Diagnosed locally recurrent incident cases\u00a0of urothelial bladder cancer by stage progession.<\/li>\n<li>Diagnosed incident cases\u00a0of metastatic recurrent urothelial bladder cancer.<\/li>\n<li>Diagnosed prevalent cases of urothelial bladder cancer.<\/li>\n<li>Drug-treatable non-muscle-invasive urothelial bladder cancer.<\/li>\n<li>Drug-treatable localized and resectable locally advanced muscle-invasive urothelial bladder cancer.<\/li>\n<li>Diagnosed unresectable locally advanced or metastatic urothelial bladder cancer 1st line\u00a0drug-treatable population.<\/li>\n<\/ul>\n<p>\u2026 and many more (details available on request).<\/p>\n<p>Note: Coverage may vary by country and region.<\/p>\n","protected":false},"template":"","class_list":["post-249985","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-bladder-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-epidemiology","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249985","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249985\/revisions"}],"predecessor-version":[{"id":571929,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/249985\/revisions\/571929"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=249985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}